D Grahame Hardie Selected Research

acadesine

1/2016	AMP-activated protein kinase inhibits Kv 1.5 channel currents of pulmonary arterial myocytes in response to hypoxia and inhibition of mitochondrial oxidative phosphorylation.
10/2008	AMP-activated protein kinase and hypoxic pulmonary vasoconstriction.
3/2004	AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D Grahame Hardie Research Topics

Disease

24	Neoplasms (Cancer) 01/2022 - 01/2003
19	Hypoxia (Hypoxemia) 01/2022 - 10/2002
18	Type 2 Diabetes Mellitus (MODY) 05/2020 - 08/2002
14	Starvation 01/2020 - 08/2003
9	Insulin Resistance 12/2013 - 06/2003
6	Obesity 05/2020 - 01/2004
4	Hypertrophy 08/2017 - 02/2005
4	Infections 06/2010 - 05/2002
3	Body Weight (Weight, Body) 07/2017 - 01/2005
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2015 - 12/2003
3	Inflammation (Inflammations) 10/2013 - 01/2013
3	Hepatocellular Carcinoma (Hepatoma) 09/2012 - 02/2005
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2016
2	Pulmonary Hypertension 05/2020 - 01/2016
2	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 08/2017 - 10/2007
2	Heart Diseases (Heart Disease) 01/2008 - 05/2003
1	Hypercapnia 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Sleep Apnea Syndromes (Sleep Apnea) 05/2020
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 05/2020
1	Metabolic Diseases (Metabolic Disease) 05/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019
1	Lymphoma (Lymphomas) 01/2019
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019
1	Carcinogenesis 01/2018
1	Morbid Obesity 01/2018
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2018
1	Cardiomegaly (Heart Hypertrophy) 08/2017
1	Diabetes Complications 01/2017
1	Hyperglycemia 01/2016
1	Acquired Immunodeficiency Syndrome (AIDS) 05/2015
1	Non-alcoholic Fatty Liver Disease 12/2013

Drug/Important Bio-Agent (IBA)

36	AMP-Activated Protein KinasesIBA 01/2022 - 06/2002
16	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 06/2002
16	Metformin (Glucophage)FDA LinkGeneric 01/2019 - 08/2002
13	Phosphotransferases (Kinase)IBA 01/2022 - 10/2002
12	Protein Isoforms (Isoforms)IBA 05/2020 - 06/2002
12	Adenosine Monophosphate (AMP)IBA 01/2019 - 10/2002
12	Adenosine Triphosphate (ATP)IBA 01/2017 - 10/2002
9	Pharmaceutical PreparationsIBA 01/2017 - 08/2002
5	LipidsIBA 04/2011 - 01/2005
4	BiguanidesIBA 01/2019 - 01/2007
4	Oxygen (Dioxygen)IBA 10/2018 - 01/2006
4	GlycogenIBA 08/2017 - 06/2002
4	Proteins (Proteins, Gene)FDA Link 01/2016 - 11/2004
4	Insulin (Novolin)FDA Link 12/2013 - 06/2003
4	CarbonIBA 09/2011 - 04/2005
3	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2022 - 01/2016
3	Protein Kinases (Protein Kinase)IBA 01/2022 - 06/2002
3	Phenformin (Fenformin)IBA 01/2019 - 12/2005
3	acadesineIBA 01/2016 - 03/2004
3	Biological ProductsIBA 01/2016 - 08/2011
3	SalicylatesIBA 09/2015 - 07/2013
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2013 - 10/2012
3	Ion Channels (Ion Channel)IBA 01/2012 - 03/2007
3	AICA ribonucleotide (ZMP)IBA 01/2012 - 03/2007
2	Sirolimus (Rapamycin)FDA Link 08/2017 - 11/2004
2	UbiquitinIBA 01/2017 - 08/2010
2	Adenosine Diphosphate (ADP)IBA 01/2017 - 10/2012
2	4- hydroxy- 3- (4- (2- hydroxyphenyl)phenyl)- 6- oxo- 7H- thieno(2,3- b)pyridine- 5- carbonitrileIBA 01/2016 - 01/2012
2	Fatty Acids (Saturated Fatty Acids)IBA 12/2013 - 11/2005
2	salicylsalicylic acid (salsalate)IBA 10/2013 - 07/2013
2	Acetyl-CoA CarboxylaseIBA 10/2008 - 10/2002
2	ThiazolidinedionesIBA 01/2008 - 01/2007
2	Hypoglycemic Agents (Hypoglycemics)IBA 07/2006 - 12/2003
2	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2006 - 12/2005
2	Cyclic ADP-Ribose (cADPR)IBA 01/2006 - 12/2005
2	LeptinIBA 03/2005 - 01/2005
2	EnzymesIBA 02/2005 - 10/2002
2	Glycogen Synthase (Synthase I)IBA 06/2003 - 06/2002
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2022
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	Calcium-Calmodulin-Dependent Protein Kinase KinaseIBA 01/2022
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2022
1	CalciumIBA 01/2022
1	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 10/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2018
1	Etoposide (VP 16)FDA LinkGeneric 01/2018
1	A-Form DNA (A-DNA)IBA 01/2018
1	CystathionineIBA 08/2017
1	SU 6656IBA 07/2017
1	src-Family KinasesIBA 07/2017
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2016
1	diphenyl (biphenyl)IBA 01/2016
1	empagliflozinIBA 01/2016
1	phosphine (phosphane)IBA 01/2016
1	CanagliflozinIBA 01/2016
1	PhlorhizinIBA 01/2016
1	dapagliflozinIBA 01/2016
1	Cisplatin (Platino)FDA LinkGeneric 01/2016
1	Sodium-Glucose Transport ProteinsIBA 01/2016
1	PoisonsIBA 01/2016
1	paxillineIBA 01/2016
1	Methotrexate (Mexate)FDA LinkGeneric 02/2015
1	Antirheumatic Agents (DMARD)IBA 02/2015
1	Hormones (Hormone)IBA 12/2013

Therapy/Procedure

2	Therapeutics 02/2011 - 02/2011
1	Oral Administration 01/2019
1	Drug Therapy (Chemotherapy) 01/2016
1	bitter melon extract 01/2016